Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley
Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania ...
BUCKSCO.Today on MSN2d
BioNTech Agrees to Pay $467M to Penn as Part of COVID-19 Vaccine Royalties Settlement
University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine royalties, writes John George ...
WESA10h
Penn expecting $467M windfall from COVID-19 vaccine royalty dispute
The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...
WHYY3d
Penn expecting $467M windfall from COVID-19 vaccine royalty dispute
plus another $15 million to fund BioNTech and University of Pennsylvania vaccine alliance research for another three years as part of the settlement. Finally, the company will contribute $52 million ...
Billy Penn5d
BP ’24 year in review: Support Billy Penn in 2025; A record warm year | Morning roundup
In Review 805 articles and counting2,837 new Instagram followers1,771 new Bluesky followers It was quite a year. Join us in ...
Reuters6d
Public Health
France reports bird flu on two farms, losing disease-free status Healthcare & Pharmaceuticalscategory· December 31, 2024 BioNTech has entered into two separate settlement agreements with the U.S ...
Reuters4d
Corporate Structure
Wall St finishes down after sell-off at end of strong holiday-shortened week December 28, 2024 BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of ...
pharmaphorum1d
A history of Pfizer
In 2009, Pfizer faced more than $2 billion in legal settlement payments over marketing ... vaccine approved – via its collaboration with BioNTech – it feels like we're only on the cusp of ...